Ribociclib plus letrozole in male patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: subgroup analysis of the phase IIIb CompLEEment-1 trial
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Ribociclib plus letrozole in male patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: subgroup analysis of the phase IIIb CompLEEment-1 trial
Authors
Keywords
-
Journal
BREAST CANCER RESEARCH AND TREATMENT
Volume 193, Issue 1, Pages 95-103
Publisher
Springer Science and Business Media LLC
Online
2022-02-25
DOI
10.1007/s10549-022-06543-1
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- LBA17 Overall survival (OS) results from the phase III MONALEESA-2 (ML-2) trial of postmenopausal patients (pts) with hormone receptor positive/human epidermal growth factor receptor 2 negative (HR+/HER2−) advanced breast cancer (ABC) treated with endocrine therapy (ET) ± ribociclib (RIB)
- (2021) G.N. Hortobagyi et al. ANNALS OF ONCOLOGY
- Full population results from the core phase of CompLEEment-1, a phase 3b study of ribociclib plus letrozole as first-line therapy for advanced breast cancer in an expanded population
- (2021) Michelino De Laurentiis et al. BREAST CANCER RESEARCH AND TREATMENT
- Cancer statistics, 2020
- (2020) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Management of Male Breast Cancer: ASCO Guideline
- (2020) Michael J. Hassett et al. JOURNAL OF CLINICAL ONCOLOGY
- 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5)†
- (2020) F. Cardoso et al. ANNALS OF ONCOLOGY
- Cancer statistics, 2019
- (2019) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- The molecular genetic make-up of male breast cancer
- (2019) Cathy B Moelans et al. ENDOCRINE-RELATED CANCER
- Overall Survival with Ribociclib plus Endocrine Therapy in Breast Cancer
- (2019) Seock-Ah Im et al. NEW ENGLAND JOURNAL OF MEDICINE
- Male breast cancer in the United States: Treatment patterns and prognostic factors in the 21st century
- (2019) Siddhartha Yadav et al. CANCER
- FDA Approval Summary: Palbociclib for Male Patients with Metastatic Breast Cancer
- (2019) Suparna Wedam et al. CLINICAL CANCER RESEARCH
- Global burden of breast cancer and attributable risk factors in 195 countries and territories, from 1990 to 2017: results from the Global Burden of Disease Study 2017
- (2019) Na Li et al. Journal of Hematology & Oncology
- Overall Survival with Ribociclib plus Fulvestrant in Advanced Breast Cancer
- (2019) Dennis J. Slamon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer
- (2018) G N Hortobagyi et al. ANNALS OF ONCOLOGY
- Cancer statistics, 2018
- (2018) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Phase III Randomized Study of Ribociclib and Fulvestrant in Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer: MONALEESA-3
- (2018) Dennis J. Slamon et al. JOURNAL OF CLINICAL ONCOLOGY
- Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial
- (2018) Debu Tripathy et al. LANCET ONCOLOGY
- Abstract CT069: Baseline gene expression patterns of CDK4/6 inhibitor-naïve or -refractory HR+, HER2- advanced breast cancer in the phase Ib study of ribociclib plus everolimus plus exemestane
- (2018) Aditya Bardia et al. CANCER RESEARCH
- Treatment of advanced HR+/HER2− breast cancer with new targeted agents in combination with endocrine therapy: a review of efficacy and tolerability based on available randomized trials on everolimus, ribociclib, palbociclib and abemaciclib
- (2018) Tea M. Bøttcher et al. ACTA ONCOLOGICA
- Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer
- (2016) Gabriel N. Hortobagyi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Role of gonadotropin-releasing hormone analogues in metastatic male breast cancer: results from a pooled analysis
- (2015) Luigi Di Lauro et al. Journal of Hematology & Oncology
- Mechanisms of Resistance to Endocrine Therapy in Breast Cancer: Focus on Signaling Pathways, miRNAs and Genetically Based Resistance
- (2012) Rocío García-Becerra et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Mechanisms of Endocrine Resistance in Breast Cancer
- (2010) C. Kent Osborne et al. Annual Review of Medicine
- Cancer Statistics, 2010
- (2010) A. Jemal et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Male breast cancer
- (2009) Laura Ottini et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now